Get started
Work

Risk of Cardiovascular Disease and Cancer in Patients Initiating JAK Versus IL‐4/‐13 Inhibitors for Atopic Dermatitis

Year: 2025
Type: article
Abstract: cardiovascular disease | dupilumab | eczema | malignancy | tofacitinib | upadacitinib JAK inhibitors (JAKi) are highly effective for treating atopic dermatitis (AD).However, concerns about cardiovascular and cancer risk persist, as their elevated risk was observed in the ORAL surveillance trial of rheumatoid arthritis (RA) [1].While the RA and AD populations likely differ, AD is independently associated with an increased risk of cardiovascular disease and cancer compared with the general population [2, 3].We aimed to compare the risk of cardiovascular disease and cancer between
DOI: 10.1111/ijd.17815
Institutions: University of Manchester, Manchester University NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, TriNetX (United States), University of Liverpool, Aintree University Hospitals NHS Foundation Trust, Aintree University Hospital
Language: English
Subfield: Dermatology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $4,150
Awards: G1483213741, G1612446978, G1798610363, G2394657754, G4123247235, G4736680341, G6694894702, Centre for Epidemiology Arthritis UK, G755762994, Centre for Genetics and Genomics Arthritis UK
OpenAlex ID: W4409869957
FWCI: 2.463
Cites: 5
Cited by: 3
Related to: 10